Dr. Shannon Puhalla on PALOMA-3 Updates

Shannon Puhalla, MD
Published: Thursday, Aug 13, 2015



Shannon Puhalla, MD, assistant professor of Medicine, University of Pittsburgh, discusses recent updates of the PALOMA3- trial.

PALOMA-3 was a phase III trial of targeted drug palbociclib in combination with hormone therapy fulvestrant in women with relapsed, metastatic hormone receptor-positive, HER2-negative breast cancer.

The study found a 6-month improvement in progression-free survival (PFS) with palbociclib. There were high rate of neutropenia with palbociclib compared to fulvestrant alone.

SELECTED
LANGUAGE


Shannon Puhalla, MD, assistant professor of Medicine, University of Pittsburgh, discusses recent updates of the PALOMA3- trial.

PALOMA-3 was a phase III trial of targeted drug palbociclib in combination with hormone therapy fulvestrant in women with relapsed, metastatic hormone receptor-positive, HER2-negative breast cancer.

The study found a 6-month improvement in progression-free survival (PFS) with palbociclib. There were high rate of neutropenia with palbociclib compared to fulvestrant alone.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x